Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis.
OBJECTIVE
To assess circulating levels of derived reactive oxygen metabolites (ROMs) in patients with active rheumatoid arthritis (RA), before and during antitumour necrosis factor (TNF)-α therapy.


METHODS
Patients with active RA and failed previous treatment with disease-modifying antirheumatic drugs received subcutaneous anti-TNF-α for 52 weeks. Circulating hydrogen peroxide was quantified as a marker of oxidative stress at baseline and at 24 and 52 weeks.


RESULTS
The study included 40 patients. Circulating dROM levels were significantly reduced compared with baseline after 24 and 52 weeks' of anti-TNF-α treatment (33.2 ± 10.0 mgH2O2/dl, 29.5 ± 7.0 mgH2O2/dl and 29.3 ± 9.0 mgH2O2/dl, respectively). There was a significant direct correlation between disease activity score and ROM levels.


CONCLUSIONS
TNF-α inhibition can control disease activity and reduce circulating levels of reactive oxygen species in patients with RA.
Internal Medicine Unit and Rheumatology Clinic - N. Melli Hospital, San Pietro Vernotico, Brindisi, Italy f.cacciapaglia@unicampus.it.
Fabio
F
Cacciapaglia
Department of Medicine - Rheumatology Unit, Medical School, University of Bari, Bari, Italy.
Maria
M
Grazia Anelli
Morelli & Di Pierro Lab, Squinzano, Lecce, Italy.
Daniela
D
Rizzo
Morelli & Di Pierro Lab, Squinzano, Lecce, Italy.
Emma
E
Morelli
Internal Medicine Unit and Rheumatology Clinic - N. Melli Hospital, San Pietro Vernotico, Brindisi, Italy.
Daniela
D
Mazzotta
Department of Medicine - Rheumatology Unit, Medical School, University of Bari, Bari, Italy.
Crescenzio
C
Scioscia
Department of Medicine - Rheumatology Unit, Medical School, University of Bari, Bari, Italy.
Florenzo
F
Iannone
Department of Medicine - Rheumatology Unit, Medical School, University of Bari, Bari, Italy.
Giovanni
G
Lapadula
Anti-TNF; ROS; disease activity; oxidative stress; reactive oxygen metabolites; rheumatoid arthritis
Clin Rheumatol. 2014 Nov;33(11):1557-64
24718487
J Nutr. 2001 Dec;131(12):3208-11
11739867
Autoimmun Rev. 2012 Jun;11(8):604-9
22041580
Rheumatol Int. 2011 Apr;31(4):451-6
20024554
Best Pract Res Clin Rheumatol. 2011 Apr;25(2):249-70
22094200
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):253-62
16198162
J Rheumatol. 2015 Oct;42(10):1767-80
26178281
Eur Heart J. 2014 Jul 14;35(27):1782-91
24864079
Clin Exp Immunol. 2003 Mar;131(3):398-404
12605691
Arthritis Rheum. 2010 Sep;62(9):2569-81
20872595
Atherosclerosis. 2012 Oct;224(2):309-17
22673743
Clin Exp Rheumatol. 2009 Jul-Aug;27(4):552-9
19772784
Clin Exp Rheumatol. 2008 Jan-Feb;26(1):73-80
18328150
Vet Res Commun. 2008 Feb;32(2):137-43
17846911
Autoimmun Rev. 2011 Aug;10(10):599-608
21545847
Circ Res. 2002 Aug 23;91(4):281-91
12193460
Clin Rheumatol. 2014 Jul;33(7):877-84
24510026
Eur J Heart Fail. 2002 Aug;4(4):559-61
12167397
J Atheroscler Thromb. 2012;19(8):712-7
22785135
Ann N Y Acad Sci. 2007 Jun;1108:349-58
17893998
Arthritis Res Ther. 2011 Jul 25;13(4):R121
21787418
Autoimmun Rev. 2011 Aug;10(10):631-5
21539939
Int J Biochem Cell Biol. 2007;39(1):44-84
16978905
Curr Atheroscler Rep. 2012 Jun;14(3):264-76
22350585
Clin Exp Rheumatol. 2013 Jan-Feb;31(1):122-4
23101488